AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
nialamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1907 | 51-12-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An MAO inhibitor that is used as an antidepressive agent.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
| S (Water solubility) | 2.27 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK1,GRK2,GRK3,GSK3B,JAK1,JAK2,KIT,MAP3K21,MAP3K7,MAPK1,MAPK12,MAPK7,MAPK9,MARK4,NTRK2,PAK4,PDK1,PDK2,PDK4,PIK3CB,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 44 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,DYRK1B,EPHB4,ERBB2,GRK2,MARK4,PRKCD,SIK2 | 10 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AF02 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Monoamine oxidase inhibitors, non-selective |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
| MeSH PA | D011619 | Psychotropic Drugs |
| CHEBI has role | CHEBI:22586 | antioxidants |
| CHEBI has role | CHEBI:23357 | cofactor |
| CHEBI has role | CHEBI:25212 | metabolites |
| CHEBI has role | CHEBI:61115 | histone deacetylase inhibitors |
| CHEBI has role | CHEBI:62913 | PARP |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agents |
| CHEBI has role | CHEBI:71181 | Sir2 inhibitors |
| CHEBI has role | CHEBI:75771 | Mus musculus metabolites |
| CHEBI has role | CHEBI:75772 | S. cerevisiae metabolites |
| CHEBI has role | CHEBI:76971 | Escherichia coli metabolites |
| CHEBI has role | CHEBI:84087 | human urinary metabolites |
| CHEBI has role | CHEBI:176497 | geroprotectors |
Related Drugs by ATC class:
N06AF Monoamine oxidase inhibitors, non-selective 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.18 | acidic |
| pKa2 | 12.9 | acidic |
| pKa3 | 3.65 | Basic |
| pKa4 | 0.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000167319 | NUI |
| D07337 | KEGG_DRUG |
| C0027999 | UMLSCUI |
| CHEBI:94510 | CHEBI |
| CHEMBL1256841 | ChEMBL_ID |
| DB04820 | DRUGBANK_ID |
| D009526 | MESH_DESCRIPTOR_UI |
| 4472 | PUBCHEM_CID |
| 899 | INN_ID |
| T2Q0RYM725 | UNII |
| 7394 | RXNORM |
| 001494 | NDDF |
| 49313009 | SNOMEDCT_US |
| T2Q0RYM725 | INXIGHT DRUGS |
Pharmaceutical products:
None